Nalaganje...
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B...
Shranjeno v:
| izdano v: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5267378/ https://ncbi.nlm.nih.gov/pubmed/28122590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0403-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|